Innovent Biologics, Inc.’s $403.1 Million Initial Public Offering

Davis Polk advised the underwriters and joint global coordinators in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Michael Patrini

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here